Literature DB >> 26808164

Insight into SUCNR1 (GPR91) structure and function.

Julie Gilissen1, François Jouret2, Bernard Pirotte3, Julien Hanson4.   

Abstract

SUCNR1 (or GPR91) belongs to the family of G protein-coupled receptors (GPCR), which represents the largest group of membrane proteins in human genome. The majority of marketed drugs targets GPCRs, directly or indirectly. SUCNR1 has been classified as an orphan receptor until a landmark study paired it with succinate, a citric acid cycle intermediate. According to the current paradigm, succinate triggers SUCNR1 signaling pathways to indicate local stress that may affect cellular metabolism. SUCNR1 implication has been well documented in renin-induced hypertension, ischemia/reperfusion injury, inflammation and immune response, platelet aggregation and retinal angiogenesis. In addition, the SUCNR1-induced increase of blood pressure may contribute to diabetic nephropathy or cardiac hypertrophy. The understanding of SUCNR1 activation, signaling pathways and functions remains largely elusive, which calls for deeper investigations. SUCNR1 shows a high potential as an innovative drug target and is probably an important regulator of basic physiology. In order to achieve the full characterization of this receptor, more specific pharmacological tools such as small-molecules modulators will represent an important asset. In this review, we describe the structural features of SUCNR1, its current ligands and putative binding pocket. We give an exhaustive overview of the known and hypothetical signaling partners of the receptor in different in vitro and in vivo systems. The link between SUCNR1 intracellular pathways and its pathophysiological roles are also extensively discussed.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; GPR91; Hypertension; Ischemia–reperfusion injury; SUCNR1; Succinate

Mesh:

Substances:

Year:  2016        PMID: 26808164     DOI: 10.1016/j.pharmthera.2016.01.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  30 in total

1.  A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions.

Authors:  Céline Laschet; Nadine Dupuis; Julien Hanson
Journal:  J Biol Chem       Date:  2018-12-28       Impact factor: 5.157

2.  Identification and pharmacological characterization of succinate receptor agonists.

Authors:  Pierre Geubelle; Julie Gilissen; Sébastien Dilly; Laurence Poma; Nadine Dupuis; Céline Laschet; Dayana Abboud; Asuka Inoue; François Jouret; Bernard Pirotte; Julien Hanson
Journal:  Br J Pharmacol       Date:  2017-03-10       Impact factor: 8.739

3.  Dietary succinate supplementation to maternal mice improves fetal brown adipose tissue development and thermogenesis of female offspring.

Authors:  Xiangdong Liu; Yanting Chen; Liang Zhao; Qiyu Tian; Jeanene Marie deAvila; Mei-Jun Zhu; Min Du
Journal:  J Nutr Biochem       Date:  2021-11-18       Impact factor: 6.048

4.  Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells.

Authors:  Ilaria Elia; Jared H Rowe; Sheila Johnson; Shakchhi Joshi; Giulia Notarangelo; Kiran Kurmi; Sarah Weiss; Gordon J Freeman; Arlene H Sharpe; Marcia C Haigis
Journal:  Cell Metab       Date:  2022-07-11       Impact factor: 31.373

5.  Adipose-Derived Mesenchymal Stem Cells Reprogram M1 Macrophage Metabolism via PHD2/HIF-1α Pathway in Colitis Mice.

Authors:  Yin Yuan; Shuo Ni; Aoxiang Zhuge; Lanjuan Li; Bo Li
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

6.  Increased succinate receptor GPR91 involved in the pathogenesis of Mooren's ulcer.

Authors:  Lin Li; Yan-Ling Dong; Ting Liu; Dan Luo; Chao Wei; Wei-Yun Shi
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

7.  SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity.

Authors:  Noelia Keiran; Victoria Ceperuelo-Mallafré; Enrique Calvo; Maria Isabel Hernández-Alvarez; Miriam Ejarque; Catalina Núñez-Roa; Daniel Horrillo; Elsa Maymó-Masip; M Mar Rodríguez; Rosa Fradera; Juan Vladimir de la Rosa; Rosa Jorba; Ana Megia; Antonio Zorzano; Gema Medina-Gómez; Carolina Serena; Antonio Castrillo; Joan Vendrell; Sonia Fernández-Veledo
Journal:  Nat Immunol       Date:  2019-04-08       Impact factor: 25.606

8.  A Metabolite-Triggered Tuft Cell-ILC2 Circuit Drives Small Intestinal Remodeling.

Authors:  Christoph Schneider; Claire E O'Leary; Jakob von Moltke; Hong-Erh Liang; Qi Yan Ang; Peter J Turnbaugh; Sridhar Radhakrishnan; Michael Pellizzon; Averil Ma; Richard M Locksley
Journal:  Cell       Date:  2018-06-07       Impact factor: 41.582

9.  Succinate promotes skeletal muscle protein synthesis via Erk1/2 signaling pathway.

Authors:  Yexian Yuan; Yaqiong Xu; Jingren Xu; Bingqing Liang; Xingcai Cai; Canjun Zhu; Lina Wang; Songbo Wang; Xiaotong Zhu; Ping Gao; Xiuqi Wang; Yongliang Zhang; Qingyan Jiang; Gang Shu
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

10.  Short-term succinic acid treatment mitigates cerebellar mitochondrial OXPHOS dysfunction, neurodegeneration and ataxia in a Purkinje-specific spinocerebellar ataxia type 1 (SCA1) mouse model.

Authors:  Austin Ferro; Emily Carbone; Jenny Zhang; Evan Marzouk; Monica Villegas; Asher Siegel; Donna Nguyen; Thomas Possidente; Jessilyn Hartman; Kailen Polley; Melissa A Ingram; Georgia Berry; Thomas H Reynolds; Bernard Possidente; Kimberley Frederick; Stephen Ives; Sarita Lagalwar
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.